Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Summary of recent changes (last updated March 3, 2021):
Clinical considerations added for use of Janssen (Johnson & Johnson) COVID-19 vaccine.
Updated recommendations for fully vaccinated people who subsequently develop COVID-19.
Updated recommendations related to COVID-19 vaccination timing for immunocompromised people.
Updated contraindications and precautions to mRNA COVID-19 vaccines.
Updated information on interpretation of SARS-CoV-2 antibody test results after vaccination.

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html